Plaque Psoriasis

FDA approved risankizumab for children aged 6 years or older with plaque psoriasis or active psoriatic arthritis.

Dawn Eichenfield, MD, PhD, discusses differential diagnosis, off-label treatment rationale, and multidisciplinary care for rare and atypical skin conditions in children.

LATITUDE Atlas saw more than 35% of patients receiving zasocitinib 30 mg once daily reaching a PASI100 response at week 16, the primary endpoint.

This preview of the 2026 SDPA Summer Dermatology Conference highlights different sessions and interviews covered by the HCPLive team.

This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.

The Genital Psoriasis Wellness Consortium reached consensus on age-specific recommendations on screening, care, and special populations.

This Q&A interview highlights the broader implications of the phase 3b TOGETHER-PsO trial for ixekizumab and tirzepatide in managing psoriatic disease.

Adults with difficult-to-treat psoriasis due to overweight or obesity saw notable benefits to both with concomitant ixekizumab and tirzepatide.

Treatment-associated phenotype switching between psoriasis and atopic dermatitis was noted to be reproducible and bidirectional in real-world clinical settings.

Investigators released long-term data on long-term bimekizumab use in psoriasis suggest, demonstrating sustained efficacy through 4 years.

This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.

In this Q&A interview, Bhatia discusses the FDA's recent acceptance of BLA for imsidolimab for generalized pustular psoriasis (GPP).

These Week 16, phase 2a findings from the EVERLAST-A study assessing ORKA-001 highlight the treatment's potential in those with plaque psoriasis.

Armstrong spoke in an interview regarding several different sessions presented at the 2026 AAD meeting.

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

This Q&A interview from AAD 2026 covers a number of notable tips for clinicians in dermatology regarding topical therapies.

This review of dermatology news from the first quarter of 2026 highlights key headlines, FDA news, and more.

This summary of March 2026 highlights key news and developments in the dermatology news space.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Check out exclusive expert interviews of late breaking data from AAD 2026.

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.